CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)

Interventions

DRUG

CAR-T Therapy

CT1190B cells infusion

Trial Locations (1)

RECRUITING

Beijing GoBroad Hospital, Beijing